Creating a New Kind of Doctor
We recruit and train physician leaders as comfortable taking on systemic challenges in health as caring for individual patients.
ARE YOU ONE?
Discovery to Impact — Faster
We reward creative thinking and encourage rapid experimentation, using collaborative programs to speed promising research to market.
SEE HOW
Improving Care. Improving Health.
We’re here to make health — including health care — better. The end goal is a complete revolution in how people get and stay healthy.
WHAT IT MEANS
In This Section
More Information
GET CARE
Health in the Landscape of Life
Enabling the healthscape, the ecosystem outside the clinic, requires improving the system to pay for health drivers.
EXPLORE FURTHER
More Information
DEVELOP A PRODUCT
Meet Dell Med
We’re rethinking the role of academic medicine in improving health — and doing so with a unique focus on our community.
ABOUT US
More Information
EXPLORE
Make an Appointment Give Faculty Students Alumni Directory

Claudia F. Lucchinetti, M.D.

Education

M.D.
Rush Medical College

B.S., Biology
Northwestern University

Residency/Fellowship

Residency, Neurology
Mayo Clinic College of Medicine and Science

Fellowship, Neuroimmunology
Mayo Clinic College of Medicine and Science

Mayo Foundation Scholar in Neuropathology
Brain Research Institute University of Vienna, Austria

About

Claudia F. Lucchinetti, M.D., serves as dean of Dell Medical School and senior vice president for medical affairs at The University of Texas at Austin. In these roles, she oversees Dell Med’s work in education, research and clinical care, including operations at UT Health Austin, Dell Med’s clinical practice, and leads the university’s comprehensive health care strategy. She also holds the Frank and Charmaine Denius Distinguished Dean’s Chair in Medical Leadership.

A neurologist with specialization in neuroimmunology and experimental neuropathy, she is an internationally recognized expert in the clinical and neuropathological underpinnings of the broad spectrum of inflammatory demyelinating diseases, including multiple sclerosis, neuromyelitis optica and MOG antibody associated disease.

Lucchinetti comes to Austin from Mayo Clinic in Rochester, Minnesota, where she is dean of clinical and translational science and director of the Center for Clinical and Translational Science. She also serves as chair of the Department of Neurology and chair of the neurology enterprise subspecialty council, overseeing strategic and operational responsibilities across Mayo Clinic sites nationwide. She is the Eugene and Marcia Applebaum Professor of Neurosciences and a professor of neurology at Mayo Clinic Alix School of Medicine, and she serves on the Mayo Clinic Board of Governors and Board of Trustees.

She earned her medical degree from Rush Medical College in Chicago and, after an internship at Rush-Presbyterian-St. Luke’s Medical Center, completed a neurology residency and a fellowship in neuroimmunology at Mayo Clinic College of Medicine and Science. As a Mayo Foundation Scholar, she trained in experimental neuropathology with Hans Lassmann, M.D., at the Brain Research Institute in Vienna, Austria.

Lucchinetti’s research contributions include a landmark study describing four patterns of tissue damage in early multiple sclerosis; it suggested that MS lesions form differently among patient subgroups. This work markedly refined medicine’s understanding of the disease, indicating the potential for individualized therapy based on pathological subtype.

Following paradigm-changing research that found evidence for early inflammatory cortical damage in MS, Lucchinetti was the first to propose that the disease progresses from the outermost layers of the brain before extending into deeper regions. As a result, scientists and physicians better understand the sequence and timing of damage to the nervous system resulting from MS, leading to novel imaging biomarkers of the disease and new treatment strategies.

She was also first to propose that based on pathology, neuromyelitis optica, a condition where the immune system damages the spinal cord and the nerves of the eyes, was an antibody-mediated disease targeting the perivascular space and, with a team of Mayo collaborators led by Vanda Lennon, M.D., identified the first biomarker targeting the water channel expressed on astrocytes, a subtype of glial cells. These and subsequent studies have reshaped our understanding of neuromyelitis optica and its relationship to MS and opened a field of research into the roles of astrocytes in the central nervous system.

Lucchinetti has been the recipient of significant research grant funding from the National Multiple Sclerosis Society, the National Institute of Neurological Disorders and Stroke, the National Center for Advancing Translational Sciences and the U.S. Department of Defense. She is also on the Council of the National Institute of Neurological Disorders and Stroke and the recipient of numerous awards, including the 2016 John Dystel Prize for MS Research.

To date, she has authored more than 220 peer-reviewed articles, with an h-index of 88.

Professional Affiliations
  • Association of University Professors of Neurology
    Board of Directors
  • American Neurological Association
    Board of Directors
  • National Institute of Neurological Disorders and Stroke
    Council Member
  • American Academy of Neurology
    Fellow
  • Sigma Xi
    Member
Awards & Honors
  • Irvine Levy Visiting Lectureship
    Washington University in St. Louis, 2020
  • William Sheremata Lectureship
    University of Miami, 2019
  • Robert Wartenburg Memorial Lecture
    American Academy of Neurology, 2019
  • John Dystel Prize for Multiple Sclerosis Research
    American Academy of Neurology and the National Multiple Sclerosis Society, 2016
  • Outstanding Teacher Award
    Mayo Clinic College of Medicine and Science, 2014
  • Frontiers in Neuroscience Award
    American Academy of Neurology, 2002